The FDA throws out the company’s second attempt at an accelerated approval.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.

Meanwhile, Bristol’s other competition in this disease looks set to come from China.

SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.

A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.

After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.

The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.